These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34260519)

  • 1. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.
    Zheng X; Wang W; Wang G; Liu S
    Medicine (Baltimore); 2021 Jul; 100(28):e25002. PubMed ID: 34260519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
    Gao R; Zhang Y; Hou W; Li J; Zhu G; Zhang X; Xu B; Wu Z; Wang H
    Trials; 2021 Mar; 22(1):214. PubMed ID: 33731199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
    Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
    Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
    Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
    Hu L; Liang G; Yuliang W; Bingjing Z; Xiangdong Z; Rufu X
    Trials; 2013 Feb; 14():45. PubMed ID: 23413951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
    Wang XQ; Liu J; Lin HS; Hou W
    Trials; 2016 Mar; 17(1):124. PubMed ID: 26956875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.
    Xiao Z; Chen Z; Han R; Lu L; Li Z; Lin J; Hu L; Huang X; Lin L
    Medicine (Baltimore); 2021 May; 100(18):e25690. PubMed ID: 33950949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
    Paz-Ares LG; Altug S; Vaury AT; Jaime JC; Russo F; Visseren-Grul C
    BMC Cancer; 2010 Mar; 10():85. PubMed ID: 20211022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial.
    Zhou Y; Zhao B; Wu W; Yang X; Long S; Deng H; He W; Liao G; Li Q; Xie Z
    Trials; 2018 Sep; 19(1):474. PubMed ID: 30180874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
    Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
    J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
    Chen W; Lin J; Yang T; Xin Zhang Z; Tao L; Xiao Z; Chen H; Qi X; Sun L; Cao Y; Lin L
    Integr Cancer Ther; 2023; 22():15347354221151147. PubMed ID: 36710490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial.
    Xiao Z; Hu L; Lin J; Lu L; Huang X; Zhu X; Teo C; Lin L
    Trials; 2020 Jan; 21(1):94. PubMed ID: 31948475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials.
    Zhang F; Yin Y; Xu T
    Medicine (Baltimore); 2019 Aug; 98(35):e16969. PubMed ID: 31464940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.
    Xia Q; Chen G; Ren Y; Zheng T; Shen C; Li M; Chen X; Zhai H; Li Z; Xu J; Gu A; Jin M; Fan L
    BMC Cancer; 2021 Jun; 21(1):721. PubMed ID: 34157996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; Biesma B; Heigener D; von Pawel J; Eisen T; Bennouna J; Zhang L; Liao M; Sun Y; Gans S; Syrigos K; Le Marie E; Gottfried M; Vansteenkiste J; Alberola V; Strauss UP; Montegriffo E; Ong TJ; Santoro A;
    J Clin Oncol; 2012 Sep; 30(25):3084-92. PubMed ID: 22851564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
    Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
    BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.